The role of rivastigmine (exelon) in the treatment of consequences of cranial-brain trauma
Kondrat'eva, E.A.; Borovikova, V.N.; Kondrat'ev, S.A.; Driagina, N.V.; Voronenko, V.A.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 109(1): 55-58
2009
ISSN/ISBN: 1997-7298 PMID: 19156088 Document Number: 630756
The use of rivastigmine in the rehabilitation of patients with cognitive disturbances after cranial-brain trauma (CBT) is reviewed. Replacement of cholinergic deficit exerts a positive effect on sanogenetic process in the brain, facilitate consolidation and learning of afferent information in the restoring brain. The authors emphasize that the administration of neuromediator preparations needs the level of organization of integrative brain activity which is sufficient for the formation of awakening reaction (opening of eyes - awakening from coma). It is suggested that neuromediator preparations, in particular cholinesterase inhibitor rivastigmine, should be used after the acutest CBT period, i.e. at least 2-3 weeks after CBT, when the main acute processes have been stabilized.